Health7/31/2025NYT

Trisomy 18 Was Once Seen as Too Lethal to Treat. Some Kids Are Now Surviving.

The article discusses the survival of children with Trisomy 18, a genetic condition that was once considered too lethal to treat. While Trisomy 18 is typically fatal within weeks of birth, some children are now surviving longer due to advancements in medical interventions, parental determination, and sheer luck. The article highlights the stories of several families whose children with Trisomy 18 have defied the odds, living for months or even years. These children have undergone various surgeries and intensive care, often requiring constant attention and support from their dedicated parents. The article explores the ethical and medical challenges surrounding the treatment of Trisomy 18, as well as the ongoing debate about the quality of life for these children. It suggests that while survival rates have improved, the condition remains highly complex, and each case requires careful consideration and individualized decision-making. The article emphasizes the resilience and determination of the families involved, who are willing to fight for the chance to give their children more time, despite the considerable challenges they face.

Note: This is an AI-generated summary of the original article. For the full story, please visit the source link below.

Source: NYTAI-generated summary
Content is AI-generated for summary purposes only
Share:

Related Articles

Air pollution from oil and gas causes 90,000 premature US deaths each year, says new study
🏥 Health11h ago1 min read

Air pollution from oil and gas causes 90,000 premature US deaths each year, says new study

Content is AI-generated for summary purposes only
Baby boomers are not to blame for everything | Letters
🏥 Health11h ago1 min read

Baby boomers are not to blame for everything | Letters

Content is AI-generated for summary purposes only
Wes Streeting’s row with pharma firms grows as they reject NHS drug pricing offer
🏥 Health14h ago1 min read

Wes Streeting’s row with pharma firms grows as they reject NHS drug pricing offer

Content is AI-generated for summary purposes only
‘A nuisance and an eyesore’: hire ebikes accumulate at London border between rival firms
🏥 Health16h ago1 min read

‘A nuisance and an eyesore’: hire ebikes accumulate at London border between rival firms

Content is AI-generated for summary purposes only
Ministers announce clampdown on UK child benefit claims from overseas
🏥 Health18h ago1 min read

Ministers announce clampdown on UK child benefit claims from overseas

Content is AI-generated for summary purposes only
As measles gains ground in US, Texas offers lessons from its outbreak
🏥 Health19h ago1 min read

As measles gains ground in US, Texas offers lessons from its outbreak

Content is AI-generated for summary purposes only